Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aiolos Raises $245 Million; Partners Hengrui’s Asthma Drug in $1 Billion Deal

publication date: Oct 24, 2023

San Francisco's Aiolos Bio, a respiratory and inflammatory drug company, broke cover with $245 million in Series A funds and a Phase II asthma drug in-licensed from Jiangsu Hengrui Medicine. In August, Aiolos, then known as One Bio, acquired rights to Hengrui’s asthma candidate, an anti-TSLP monoclonal antibody, for $21.5-million upfront and over $1 billion in milestones plus double-digit tiered royalties. Aiolos, a San Francisco-London company, plans to start a Phase II clinical trial of the TSLP mAb in moderate-to-severe asthma patients while it considers additional acquisitions. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital